An observational study in Breast Cancer and Genetic Predisposition, sponsored by Regina Elena Cancer Institute. Recruiting at 2 sites in Italy. Open to female participants aged 25 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.
Sponsored by Regina Elena Cancer Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Breast Neoplasms by Regina Elena Cancer Institute — 7 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Regina Elena Cancer Institute.
Among the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2022, is one of 12 observational ones, and was the 8th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Regina Elena Cancer Institute · Sites in Italy
Ages 35–70 · Women only
Regina Elena Cancer Institute · Sites in Italy
Ages 18+ · Women only
Regina Elena Cancer Institute · Sites in Italy
Ages 18+ · Women only
Regina Elena Cancer Institute · Sites in Italy
Ages 18+ · Women only · Healthy volunteers
Regina Elena Cancer Institute · Sites in Italy
Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 25 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 104 across the 3 interventional studies, 134 across the 11 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regina Elena Cancer Institute is the lead sponsor of 95 studies on the registry; 51 are open to participants now.
1 of the studies in Breast Neoplasms by Regina Elena Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07256769Regina Elena Cancer InstituteVitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis | 2027-09-29 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Breast Neoplasms by Regina Elena Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Women with breast and/or ovarian cancer or with a family history carried these pathologies can makeo genetic counseling in order to investigate whether they are carriers of the BRCA1/2 genetic mutation. This mutation exposes them to develop breast cancer from 50 to 80% and from 27 to 65% of developing ovarian cancer. BRCA1/2 mutations are inherited as an autosomal dominant manner and therefore there is a 50% probability of transmitting the mutation to the progeny. For this reason, women who have BRCA 1/2 mutation may be less likely to want children than those who test negative. The decision to have children could worry both for the probability to transfer the genetic mutation or because the parenthood could be compromised by the illness and/or by premature death. In previous studies, the psychological condition of patients with BRCA 1/2 mutations, with or without children, was only partially investigated. For this reason the main goal of the study is to deeply investigate the specific psychological condition, with particular attention to the guilt feelings on the possibility to transfer the genetic mutation to the progeny. In this wai it could be useful to development a therapeutic strategies aimed at the best adaptation of the patients to the new health condition.
Women with BRCA1/2 mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Guilt feelings about procreating
Evaluation of feeling guilting
* ISGR-15s * Il PFQ-2 * PHQ-9
Time frame: 24 monts
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Dec 2023, 19 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regina Elena Cancer Institute